GLP-1 Analogues Market

Report Code PH 9080
Published in Jul, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032

Overview

The size of global GLP-1 analogues market in terms of revenue was estimated to be worth $47.4 billion in 2024 and is poised to reach $471.1 billion by 2032, growing at a CAGR of 33.2% from 2024 to 2032. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics. GLP-1 analogue drugs have gained high acceptance in recent years, especially after their benefits in treating chronic obesity and weight management became known widely. In addition, the clinical pipeline for this drug class is strong. The pipeline reveals an abundance of products (existing and innovative molecules) expected to launch during the forecast period. A few notable product instances include- Oral semaglutide (25 mg and 50 mg) for type 2 diabetes, CagriSema (a combination product of Cagrilintide and Semaglutide) for obesity as well as type 2 diabetes, Survodutide for the treatment of obesity and Nonalcoholic steatohepatitis (NASH), Semaglutide against NASH, and among others. Thus, this is a key factor driving market growth. However, more than 90% of the marketed products are offered by two key players in the market- Novo Nordisk A/S and Eli Lilly and Company. This has created a duopoly in the market. This factor thus, is expected to create high entry barriers for new entrants in the market.

Attractive Opportunities in the GLP-1 Analogues Market

NORTH AMERICA:

Growth in the North American GLP-1 analogues market can be attributed to factors such as growing investments in research initiatives for developing GLP-1 analogues, and large adoption of GLP-1 analogues in the region among others.

Growth in the GLP-1 analogues market is mainly driven by factors such as increasing focus on innovation to develop new GLP-1 analogue drugs, and a high demand for these drugs among others

The growing application of GLP-1 analogs in new therapeutic indications (NASH, Alzheimer’s disease, others) is a key opportunity area for players in the GLP-1 analogues market.

The global GLP-1 analogues market is projected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2% during the forecast period.

Globally, North America is the largest market for GLP-1 analogues, and this trend is expected to continue during the forecast period.

Global GLP-1 Analogues Market Dynamics

DRIVER: Strong R&D pipeline

GLP-1 analogues is a class of drugs referred to as incretin mimetics. These drugs aid in regulating blood glucose levels and promote satiety thus, used in the treatment of diabetes and obesity. The drugs have been in high demand for treating obesity in recent years. Also, the drug class is highly adopted for the treatment of type 2 diabetes. Therefore, many key players are in the development of novel drugs for this class. The clinical pipeline reflects a wide range of products in development, along with existing products being tested for novel indications such as Nonalcoholic Steatohhepatitis (NASH) and Alzheimer’s disease, among others. The R&D pipeline is dominated by Novo Nordisk A/S which is the leading player in this market along with some other large pharmaceutical and biopharmaceutical companies like Boehringer Ingelheim International GmbH (Survodutide), Eli Lilly and Company (Retatrutide, Orforglipron), Innovent (IBI362/Mazdutide), Hanmi Pharm (partnered with Merck; Efinopegdutide), Zealand Pharma A/S (Dapiglutide), and Pfizer, Inc. (Danuglipron), among others. Some of the key products of focus include combination products like CagriSema (combination of Cagrilintide and semaglutide) and IcoSema (combination of basal insulin icodec and semaglutide), and oral GLP-1 products.

RESTRAINT: High entry barriers due to duopoly

The market is dominated by two players- Novo Nordisk A/S (Denmark) and Eli Lilly and Company (US). These key players form a duopoly in the market for currently marketed GLP-1 analogues. Some of the key attributes of this duopoly include- strong brand recognition of the products, established geographic network through which the companies offer their GLP-1 analogues globally, and developed and established infrastructure that supports supply to meet the high demand for GLP-1 analogue drugs. Moreover, both companies have patented formulations that restrict generic drug makers from entering this space. Additionally, anticipating high demand for this GLP-1 analogues, the companies are further developing novel therapeutics of this drug class and also enhancing existing manufacturing capacity.

 

OPPORTUNITY: Extended therapeutic uses

The GLP-1 analogues have been traditionally used for the treatment of diabetes as they regulate blood glucose level. Additionally, with the observation of features such as providing enhanced satiety and slower gastric emptying, they have also been highly adopted for the treatment of obesity. The GLP-1 analogues drugs class is now being studied for its potential in the treatment of other indications such as NASH (nonalcoholic steatohepatitis), Alzheimer’s disease, Obstructive Sleep Apnea (OSA) and several cardiovascular indications. GLP-1 analogues help manage weight loss which is a key factor in managing NASH. Moreover, they have shown potential neuroprotective effects, and they possess anti-inflammatory properties that aid in mitigating the chronic inflammation associated with Alzheimer’s disease. Such factors are expected to support adoption of GLP-1 analogues for a wide range of indications.

CHALLENGE: Non-adherence to therapy after 12-24 months

The GLP-1 analogues is a drug class that has gained high adoption for the treatment of type 2 diabetes and obesity. Treatment adherence is the patient’s actions aligning with the prescribed therapeutic regimen. Thus, non-adherence refers to stopping medications before the complete treatment duration is passed, irregular consumption of doses, and not consuming medication as directed. Patients on GLP-1 analogues have been observed not adhering to the treatment post 12 months of initiation. For instance, a study of antiobesity GLP-1 drugs- Wegovy and Saxenda, reveals a drop to 32% of patients remaining on treatment by end 12 months since initiation of the treatment for Wegovy. This share is 21% for Saxenda. A few reasons noted for the same include the injectable nature of the majority of products, side effects such as nausea and vomiting, and high prices in developing economies. Disease bias or stigma, supply constraints and access to these medicinecs are few of the key reasons for patients quitting anti-obesity GLP-1s. Thus, the growing development of oral GLP-1 analogues with minimal side effects is expected to reduce the impact of this challenge.

Global GLP-1 Analogues Market Ecosystem Analysis

Prominent companies in the market include companies that have been operating for several years and possess a diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in the market include Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), and AstraZeneca (UK), among others. The GLP-1 analogues market ecosystem comprises supply-side companies as well as demand-side entities that significantly contribute to market growth. The supply-side ecosystem includes pharmaceutical and biotechnology companies, while demand-side entities include home care settings, long-term care facilities, hospitals, and specialty clinics.

 

Ozempic accounted for the largest share of the product segment in overall GLP-1 analogues industry in 2023.

On the basis of product, the GLP-1 analogues market is segmented product into Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Xultophy, Soliqua, Zepbound, Bydureon, and other products. In 2023, the Ozempic segment accounted for the largest share of the market owing to factors such as strong brand recognition for the product, and an established geographic availability globally support the growth of this segment.

The single dose segment dominates the format segment in overall GLP-1 analogues industry in 2023.

On the basis of format, the GLP-1 analogues market is segmented into single-dose, multi-dose, and tablets. Single dose accounted for the largest share of the market owing to factors like the ease of administration offered by single dose formulations. Additionally, the availability of the products in autoinjector format further eases the self-administration process. Moreover, single dose format are administered once weekly leading to higher adherence.

NORTH AMERICA Region Holds the Largest Share of the GLP-1 Analogues Market.

Geographically, the GLP-1 analogues market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The market was dominated by North America in 2023 and this dominance is anticipated to continue throughout the forecast period between 2024 and 2032. The market for GLP-1 analogues is expanding in the North America region as a result of factors like availability and access to majority of the GLP-1 analogue products and high demand for these drugs in the region for indications including type 2 diabetes and obesity.

 
 

Recent Developments of GLP-1 Analogues Market industry

  • In March 2024, the US FDA approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established CVD.
  • In November 2023, Eli Lilly and Company (US) received US FDA approval for Zepbound, an obesity treatment that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Key Market Players

KEY PLAYERS IN THE GLP-1 Analogues Market INCLUDE

Want to explore hidden markets that can drive new revenue in GLP-1 Analogues Market?

Scope of the Report

Report Attribute Details
Market Revenue in 2024 $47.4 billion
Projected Revenue by 2032 $471.1 billion
Revenue Rate Poised to Grow at a CAGR of 33.2%
Market Driver Strong R&D pipeline
Market Opportunity Extended therapeutic uses

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the GLP-1 Analogues Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
29
RESEARCH METHODOLOGY
33
EXECUTIVE SUMMARY
44
PREMIUM INSIGHTS
48
MARKET OVERVIEW
53
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Strong R&D pipeline
    - Improved relative efficacy of GLP-1 drugs
    - High demand, expanding insurance coverage, growing sales, increasing awareness, and positive outcomes
    RESTRAINTS
    - High barriers for new entrants due to duopoly
    OPPORTUNITIES
    - Extended therapeutic uses
    - Integration of GLP-1 drugs into telehealth and digital weight management programs
    CHALLENGES
    - Off-label use of GLP-1 drugs
    - High non-adherence to therapy after 12–24 months
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF GLP-1 ANALOGUES
    AVERAGE SELLING PRICES OF TOP GLP-1 ANALOGUES, BY COUNTRY/REGION
  • 5.5 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Chemical Synthesis
    - Recombinant DNA Technology
    ADJACENT TECHNOLOGIES
    - Hydrogel Depot Technology
    - Technologies for oral delivery of GLP-1 analogues
  • 5.6 PIPELINE ANALYSIS
  • 5.7 TRADE DATA
  • 5.8 PATENT ANALYSIS
    METHODOLOGY
    INNOVATION AND PATENT APPLICATIONS
    TOP APPLICANTS
  • 5.9 VALUE CHAIN ANALYSIS
  • 5.10 SUPPLY CHAIN ANALYSIS
  • 5.11 ECOSYSTEM ANALYSIS
    GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS
    GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
    GLP-1 ANALOGUES MARKET: ROLE OF END USERS
    GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES
  • 5.12 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA FOR GLP-1 ANALOGUES
  • 5.14 REGULATORY LANDSCAPE
    REGULATORY SCENARIO
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    - North America
    - Europe
    - Asia Pacific
    - Rest of the World
  • 5.15 KEY CONFERENCES & EVENTS, 2024–2025
  • 5.16 CASE STUDIES
    STUDY OF TIRZEPATIDE AS A CASE IN GLP-1 DRUGS MARKET
    OZEMPIC OFF-LABEL USE
  • 5.17 INVESTMENT AND FUNDING SCENARIO
GLP-1 ANALOGUES MARKET, BY PRODUCT
91
  • 6.1 INTRODUCTIONS
  • 6.2 OZEMPIC
    RISING ADOPTION TO SUPPORT MARKET GROWTH
  • 6.3 TRULICITY
    COMPETITOR REVENUE GROWTH TO AFFECT GROWTH
  • 6.4 MOUNJARO
    EXPONENTIAL GROWTH ANTICIPATED DUE TO HIGH ADOPTION IN NORTH AMERICA
  • 6.5 WEGOVY
    INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT GROWTH
  • 6.6 RYBELSUS
    CONVENIENCE OF ORAL ADMINISTRATION TO DRIVE MARKET
  • 6.7 SAXENDA
    DEVELOPMENT OF GENERIC VERSIONS TO SLOW GROWTH
  • 6.8 VICTOZA
    ADOPTION OF ORAL GLP-1S TO RESTRAIN MARKET GROWTH
  • 6.9 XULTOPHY
    REGULATORY APPROVALS TO SUPPORT MARKET GROWTH
  • 6.10 SOLIQUA
    COMPETITOR GLP-1 PRODUCTS THREAT TO GROWTH
  • 6.11 ZEPBOUND
    STRONG REVENUE GROWTH TO ENSURE CONTINUED PRESENCE
  • 6.12 BYDUREON
    COMPETITOR PRODUCTS TO AFFECT MARKET GROWTH
  • 6.13 OTHER PRODUCTS
GLP-1 ANALOGUES MARKET, BY FORMAT
118
  • 7.1 INTRODUCTIONS
  • 7.2 SINGLE DOSE
    HIGH ADOPTION DUE TO EASE OF ADMINISTRATION TO SUPPORT GROWTH
  • 7.3 MULTI-DOSE
    LOW COST TO ATTRACT LARGER ADOPTION
  • 7.4 TABLETS
    DEVELOPMENT OF HIGH-POTENCY GLP-1S TO SUPPORT MARKET GROWTH
GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION
128
  • 8.1 INTRODUCTION
  • 8.2 SUBCUTANEOUS ADMINISTRATION
    PEN INJECTORS
    - Ease of monitoring to support adoption
    AUTOINJECTORS
    - Advantages offered over pen injectors to support adoption
  • 8.3 ORAL ADMINISTRATION
    ELIMINATION OF NEEDLE PHOBIA AND EASE OF USE TO DRIVE COMPLIANCE
GLP-1 ANALOGUES MARKET, BY INDICATION
142
  • 9.1 INTRODUCTION
  • 9.2 DIABETES
    HIGH EFFICACY TO SUPPORT MARKET GROWTH
  • 9.3 OBESITY
    INCREASING DEMAND AND PIPELINE FOCUS ON ANTI-OBESITY GLP-1S TO DRIVE MARKET
  • 9.4 OTHER INDICATIONS
GLP-1 ANALOGUES MARKET, BY END USER
152
  • 10.1 INTRODUCTIONS
  • 10.2 HOME CARE SETTINGS
    RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
  • 10.3 LONG-TERM CARE FACILITIES
    GROWING GERIATRIC POPULATION AND RISING CHRONIC DISEASE INCIDENCE TO DRIVE MARKET
  • 10.4 HOSPITALS & SPECIALTY CLINICS
    ADOPTION OF GLP-1 FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH
GLP-1 ANALOGUES MARKET, BY REGION
163
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    NORTH AMERICA: RECESSION IMPACT
    US
    - Strategic developments by major players and R&D activities to drive market
    CANADA
    - Strong research infrastructure and availability of funding to support market growth
  • 11.3 EUROPE
    EUROPE: RECESSION IMPACT
    GERMANY
    - Improving accessibility to support market growth in Germany
    UK
    - Increasing research to evaluate efficacy and potential of GLP-1 analogues to support market growth
    FRANCE
    - Growing awareness to propel market growth
    ITALY
    - Presence of major pharmaceutical and biotechnology companies to drive market
    SPAIN
    - Favorable initiatives for research to drive market
    NETHERLANDS
    - Growing awareness and strong focus on pharmaceutical R&D to support market growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
    CHINA
    - Expansion of major biotechnology and pharmaceutical companies in China to drive market
    JAPAN
    - Growing availability of prominent GLP-1 drugs to drive market
    INDIA
    - Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
    AUSTRALIA
    - Access to GLP-1 drugs and government support to drive market
    SOUTH KOREA
    - Collaborations in obesity drugs to propel market growth
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    LATIN AMERICA: RECESSION IMPACT
    BRAZIL
    - Brazil to hold largest market share in Latin America
    MEXICO
    - Growing diabetes and obesity cases to support market growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    MIDDLE EAST: RECESSION IMPACT
    GCC COUNTRIES
    - Saudi Arabia
    - UAE
    - Rest of GCC countries
    REST OF MIDDLE EAST
  • 11.7 AFRICA
    GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
    AFRICA: RECESSION IMPACT
COMPETITIVE LANDSCAPE
249
  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 ANALOGUES MARKET
  • 12.3 REVENUE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
  • 12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company Footprint
    - Format footprint
    - Route of administration footprint
    - Indication footprint
    - Region footprint
  • 12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.8 VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 12.9 BRAND/PRODUCT COMPARISON
  • 12.10 COMPETITIVE SCENARIO
    PRODUCT APPROVALS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
272
  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYERS
    NOVO NORDISK A/S
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ELI LILLY AND COMPANY
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SANOFI
    - Business overview
    - Products offered
    - MnM view
    ASTRAZENECA
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
    - Business overview
    - Products offered
    BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    - Business overview
    - Products in pipeline
    - Recent developments
    INNOVENT
    - Business overview
    - Products in pipeline
    - Recent developments
    PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
    - Business overview
    - Products in pipeline
    SCIWIND BIOSCIENCES CO., LTD.
    - Business overview
    - Products in pipeline
    - Recent developments
    ZEALAND PHARMA A/S
    - Business overview
    - Products in pipeline
    - Recent developments
    BEIJING DONGFANG BAITAI BIOTECHNOLOGY CO., LTD (EASTERN BIOTECH)
    - Business overview
    - Products in pipeline
  • 13.3 OTHER PLAYERS
    SUN PHARMACEUTICAL INDUSTRIES LTD.
    VTV THERAPEUTICS
    TERNS PHARMACEUTICALS, INC.
    ALTIMMUNE
    SCOHIA PHARMA, INC.
    STRUCTURE THERAPEUTICS
    NEUROBO PHARMACEUTICALS, INC.
    I2O THERAPEUTICS, INC.
    AMGEN INC.
    PFIZER INC.
    MERCK & CO., INC.
    HANMI PHARM CO., LTD.
    VIKING THERAPEUTICS
    JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
APPENDIX
308
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
  • TABLE 2 GLP-1 ANALOGUES MARKET: IMPACT ANALYSIS
  • TABLE 3 AVERAGE SELLING PRICE RANGE OF TOP GLP-1 ANALOGUES (2023–2024)
  • TABLE 4 GLP-1 ANALOGUES IN CLINICAL PIPELINE (AS OF MAY 2024)
  • TABLE 5 TOP 20 PATENT OWNERS IN GLP-1 ANALOGUES MARKET, 2014–2024
  • TABLE 6 INDICATIVE LIST OF PATENTS IN GLP-1 ANALOGUES MARKET, 2022–2024
  • TABLE 7 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS
  • TABLE 8 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
  • TABLE 9 GLP-1 ANALOGUES MARKET: ROLE OF END USERS
  • TABLE 10 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES
  • TABLE 11 GLP-1 ANALOGUES MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 12 BUYING CRITERIA FOR GLP-1 ANALOGUES, BY END USER
  • TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 GLP-1 ANALOGUES MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2024–2025
  • TABLE 18 GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 19 GLP-1 ANALOGUES MARKET FOR ANTI-OBESITY PRODUCTS (MILLION UNITS)
  • TABLE 20 OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 21 NORTH AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 22 EUROPE: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 23 ASIA PACIFIC: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 24 LATIN AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 25 MIDDLE EAST: OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 26 GCC COUNTRIES: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 27 TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 28 NORTH AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 29 EUROPE: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 30 ASIA PACIFIC: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 31 LATIN AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 32 MIDDLE EAST: TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 33 GCC COUNTRIES: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 34 MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 35 NORTH AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 36 EUROPE: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 37 ASIA PACIFIC: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 38 LATIN AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 39 MIDDLE EAST: MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 40 GCC COUNTRIES: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 41 WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 42 NORTH AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 43 EUROPE: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 44 ASIA PACIFIC: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 45 LATIN AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 46 MIDDLE EAST: WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 47 GCC COUNTRIES: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 48 RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 49 NORTH AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 50 EUROPE: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 51 ASIA PACIFIC: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 52 LATIN AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 53 MIDDLE EAST: RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 54 GCC COUNTRIES: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 55 SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 56 NORTH AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 57 EUROPE: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 58 ASIA PACIFIC: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 59 LATIN AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 60 MIDDLE EAST: SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 61 GCC COUNTRIES: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 62 VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 63 NORTH AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 64 EUROPE: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 65 ASIA PACIFIC: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 66 LATIN AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 67 MIDDLE EAST: VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 68 GCC COUNTRIES: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 69 XULTOPHY MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 70 SOLIQUA MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 71 ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 72 NORTH AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 73 EUROPE: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 74 ASIA PACIFIC: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 75 LATIN AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 76 MIDDLE EAST: ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 77 GCC COUNTRIES: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 78 BYDUREON MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 79 OTHER PRODUCTS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 80 GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 81 SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 82 NORTH AMERICA: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 83 EUROPE: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 84 ASIA PACIFIC: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 85 LATIN AMERICA: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 86 MIDDLE EAST: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 87 GCC COUNTRIES: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 88 MULTI-DOSE GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 89 NORTH AMERICA: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 90 EUROPE: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 91 ASIA PACIFIC: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 92 LATIN AMERICA: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 93 MIDDLE EAST: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 94 GCC COUNTRIES: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 95 GLP-1 ANALOGUE TABLETS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 96 NORTH AMERICA: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 97 EUROPE: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 98 ASIA PACIFIC: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 99 LATIN AMERICA: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 100 MIDDLE EAST: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 101 GCC COUNTRIES: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 102 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 103 SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 104 SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 105 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 106 EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 107 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 108 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 109 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 110 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 111 GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 112 NORTH AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 113 EUROPE: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 114 ASIA PACIFIC: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 115 LATIN AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 116 MIDDLE EAST: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 117 GCC COUNTRIES: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 118 GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 119 NORTH AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 120 EUROPE: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 121 ASIA PACIFIC: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 122 LATIN AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 123 MIDDLE EAST: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 124 GCC COUNTRIES: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 125 ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 126 NORTH AMERICA: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 127 EUROPE: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 128 ASIA PACIFIC: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 129 LATIN AMERICA: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 130 MIDDLE EAST: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 131 GCC COUNTRIES: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 132 GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 133 GLP-1 ANALOGUES MARKET FOR DIABETES, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 134 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 135 EUROPE: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 136 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 137 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 138 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR DIABETES, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 139 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 140 GLP-1 ANALOGUES MARKET FOR OBESITY, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 141 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 142 EUROPE: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 143 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 144 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 145 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR OBESITY, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 146 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 147 GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 148 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 149 EUROPE: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 150 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 151 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 152 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 153 GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 154 GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 155 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 156 EUROPE: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 157 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 158 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 159 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 160 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 161 GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 162 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 163 EUROPE: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 164 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 165 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 166 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 167 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 168 GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 169 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 170 EUROPE: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 171 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 172 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 173 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 174 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 175 GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 176 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 177 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 178 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 179 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 180 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 181 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 182 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 183 US: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 184 US: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 185 US: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 186 US: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 187 US: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 188 US: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 189 CANADA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 190 CANADA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 191 CANADA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 192 CANADA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 193 CANADA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 194 CANADA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 195 EUROPE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 196 EUROPE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 197 EUROPE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 198 EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 199 EUROPE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 200 EUROPE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 201 EUROPE: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 202 GERMANY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 203 GERMANY: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 204 GERMANY: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 205 GERMANY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 206 GERMANY: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 207 GERMANY: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 208 UK: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 209 UK: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 210 UK: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 211 UK: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 212 UK: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 213 UK: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 214 FRANCE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 215 FRANCE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 216 FRANCE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 217 FRANCE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 218 FRANCE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 219 FRANCE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 220 ITALY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 221 ITALY: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 222 ITALY: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 223 ITALY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 224 ITALY: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 225 ITALY: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 226 SPAIN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 227 SPAIN: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 228 SPAIN: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 229 SPAIN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 230 SPAIN: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 231 SPAIN: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 232 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 233 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 234 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 235 NETHERLANDS: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 236 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 237 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 238 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 239 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 240 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 241 REST OF EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 242 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 243 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 244 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 245 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 246 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 247 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 248 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 249 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 250 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 251 CHINA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 252 CHINA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 253 CHINA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 254 CHINA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 255 CHINA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 256 CHINA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 257 JAPAN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 258 JAPAN: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 259 JAPAN: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 260 JAPAN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 261 JAPAN: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 262 JAPAN: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 263 INDIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 264 INDIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 265 INDIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 266 INDIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 267 INDIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 268 INDIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 269 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 270 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 271 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 272 AUSTRALIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 273 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 274 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 275 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 276 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 277 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 278 SOUTH KOREA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 279 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 280 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 281 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 282 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 283 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 284 REST OF ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 285 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 286 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 287 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 288 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 289 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 290 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 291 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 292 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 293 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 294 BRAZIL: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 295 BRAZIL: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 296 BRAZIL: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 297 BRAZIL: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 298 BRAZIL: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 299 BRAZIL: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 300 MEXICO: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 301 MEXICO: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 302 MEXICO: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 303 MEXICO: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 304 MEXICO: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 305 MEXICO: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 306 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 307 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 308 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 309 REST OF LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 310 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 311 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 312 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 313 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 314 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 315 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 316 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 317 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 318 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION)
  • TABLE 319 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 320 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 321 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 322 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 323 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 324 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 325 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
  • TABLE 326 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 327 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 328 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 329 SAUDI ARABIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 330 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 331 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 332 UAE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 333 UAE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 334 UAE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 335 UAE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 336 UAE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 337 UAE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 338 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 339 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 340 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 341 REST OF GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 342 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 343 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 344 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 345 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 346 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 347 REST OF MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 348 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 349 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 350 AFRICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
  • TABLE 351 AFRICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION)
  • TABLE 352 AFRICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
  • TABLE 353 AFRICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
  • TABLE 354 AFRICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
  • TABLE 355 AFRICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION)
  • TABLE 356 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
  • TABLE 357 GLP-1 ANALOGUES MARKET: DEGREE OF COMPETITION
  • TABLE 358 GLP-1 ANALOGUES MARKET: FORMAT FOOTPRINT
  • TABLE 359 GLP-1 ANALOGUES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
  • TABLE 360 GLP-1 ANALOGUES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
  • TABLE 361 GLP-1 ANALOGUES MARKET: INDICATION FOOTPRINT (KEY PLAYERS)
  • TABLE 362 GLP-1 ANALOGUES MARKET: INDICATION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
  • TABLE 363 GLP-1 ANALOGUES MARKET: REGION FOOTPRINT (KEY PLAYERS)
  • TABLE 364 GLP-1 ANALOGUES MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 365 GLP-1 ANALOGUES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 366 GLP-1 ANALOGUES MARKET: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 367 GLP-1 ANALOGUES MARKET: DEALS, JANUARY 2021–MAY 2024
  • TABLE 368 GLP-1 ANALOGUES MARKET: EXPANSIONS, JANUARY 2021–MAY 2024
  • TABLE 369 GLP-1 ANALOGUES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
  • TABLE 370 NOVO NORDISK A/S: COMPANY OVERVIEW
  • TABLE 371 NOVO NORDISK A/S: PRODUCTS OFFERED
  • TABLE 372 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
  • TABLE 373 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2021–APRIL 2024
  • TABLE 374 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
  • TABLE 375 ELI LILLY AND COMPANY: COMPANY OVERVIEW
  • TABLE 376 ELI LILLY AND COMPANY: PRODUCTS OFFERED
  • TABLE 377 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
  • TABLE 378 ELI LILLY AND COMPANY: DEALS, JANUARY 2021–APRIL 2024
  • TABLE 379 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2021–APRIL 2024
  • TABLE 380 SANOFI: COMPANY OVERVIEW
  • TABLE 381 SANOFI: PRODUCTS OFFERED
  • TABLE 382 ASTRAZENECA: COMPANY OVERVIEW
  • TABLE 383 ASTRAZENECA: PRODUCTS OFFERED
  • TABLE 384 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
  • TABLE 385 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY OVERVIEW
  • TABLE 386 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
  • TABLE 387 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 388 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS IN PIPELINE
  • TABLE 389 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2021–APRIL 2024
  • TABLE 390 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
  • TABLE 391 INNOVENT: COMPANY OVERVIEW
  • TABLE 392 INNOVENT: PRODUCTS IN PIPELINE
  • TABLE 393 INNOVENT: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
  • TABLE 394 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: COMPANY OVERVIEW
  • TABLE 395 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: PRODUCTS IN PIPELINE
  • TABLE 396 SCIWIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW
  • TABLE 397 SCIWIND BIOSCIENCES CO., LTD.: PRODUCTS IN PIPELINE
  • TABLE 398 SCIWIND BIOSCIENCES CO., LTD.: DEALS, JANUARY 2021–APRIL 2024
  • TABLE 399 SCIWIND BIOSCIENCES CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
  • TABLE 400 ZEALAND PHARMA A/S: COMPANY OVERVIEW
  • TABLE 401 ZEALAND PHARMA A/S: PRODUCTS IN PIPELINE
  • TABLE 402 ZEALAND PHARMA A/S: DEALS, JANUARY 2021–APRIL 2024
  • TABLE 403 ZEALAND PHARMA A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
  • TABLE 404 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: COMPANY OVERVIEW
  • TABLE 405 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: PRODUCTS IN PIPELINE
LIST OF FIGURES
 
  • FIGURE 1 GLP-1 ANALOGUES MARKET SEGMENTATION
  • FIGURE 2 GLP-1 ANALOGUES MARKET: REGIONAL SEGMENTATION
  • FIGURE 3 RESEARCH DESIGN
  • FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
  • FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
  • FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 8 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 9 CAGR PROJECTIONS: GLP-1 ANALOGUES MARKET, 2024–2032
  • FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 ANALOGUES MARKET
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 GLP-1 ANALOGUES MARKET, BY PRODUCT, 2024 VS. 2032 (USD BILLION)
  • FIGURE 13 GLP-1 ANALOGUES MARKET SHARE, BY FORMAT, 2024 VS. 2032 (USD BILLION)
  • FIGURE 14 GLP-1 ANALOGUES MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2024 VS. 2032 (USD BILLION)
  • FIGURE 15 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2024 VS. 2032 (USD BILLION)
  • FIGURE 16 GLP-1 ANALOGUES MARKET, BY END USER, 2024−2032 (USD BILLION)
  • FIGURE 17 GLP-1 ANALOGUES MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 18 IMPROVED EFFICACY OF GLP-1 DRUGS TO DRIVE MARKET GROWTH
  • FIGURE 19 DIABETES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
  • FIGURE 20 OZEMPIC TO DOMINATE MARKET IN 2032
  • FIGURE 21 DIABETES INDICATIONS TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 22 HOME CARE SETTINGS TO DOMINATE THE MARKET IN 2032
  • FIGURE 23 US TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 24 GLP-1 ANALOGUES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 US: PREVALENCE OF INDICATIONS THAT MAY RESPOND TO GLP-1 DRUGS (AS OF JANUARY 2024)
  • FIGURE 26 REVENUE SHIFT IN GLP-1 ANALOGUES MARKET
  • FIGURE 27 AVERAGE SELLING PRICE TREND, BY PRODUCT
  • FIGURE 28 PRODUCT PRICING, BY COUNTRY (2023–2024)
  • FIGURE 29 ADDITIONAL LAUNCHES OF GLP-1 DRUGS, 2025–2032
  • FIGURE 30 PHASE 3 PIPELINE, BY INDICATION
  • FIGURE 31 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024
  • FIGURE 32 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024
  • FIGURE 33 VALUE CHAIN ANALYSIS: PRODUCT DEVELOPMENT AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE
  • FIGURE 34 GLP-1 ANALOGUES MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 35 GLP-1 ANALOGUES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 36 GLP-1 ANALOGUES MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 37 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 ANALOGUES, HOSPITALS
  • FIGURE 38 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 39 NORTH AMERICA GLP-1 ANALOGUES MARKET SNAPSHOT
  • FIGURE 40 EUROPE: GLP-1 ANALOGUES MARKET SNAPSHOT
  • FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 ANALOGUES MARKET, 2021–2023
  • FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 ANALOGUES MARKET, 2023
  • FIGURE 43 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 44 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2023
  • FIGURE 45 GLP-1 ANALOGUES MARKET: COMPANY FOOTPRINT (KEY PLAYERS)
  • FIGURE 46 GLP-1 ANALOGUES MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
  • FIGURE 47 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 48 EV/EBITDA OF KEY VENDORS
  • FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 50 GLP-1 ANALOGUES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS (ANTIDIABETIC GLP-1 ANALOGUES)
  • FIGURE 51 GLP-1 ANALOGUES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS (ANTI-OBESITY GLP-1 ANALOGUES)
  • FIGURE 52 NOVO NORDISK A/S: COMPANY SNAPSHOT
  • FIGURE 53 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 54 SANOFI: COMPANY SNAPSHOT
  • FIGURE 55 ASTRAZENECA: COMPANY SNAPSHOT
  • FIGURE 56 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY SNAPSHOT
  • FIGURE 57 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • FIGURE 58 INNOVENT: COMPANY SNAPSHOT
  • FIGURE 59 ZEALAND PHARMA A/S: COMPANY SNAPSHOT

This study involved three major activities in estimating the historic, current, and forecasted size of the GLP-1 Analogues market. Exhaustive secondary research was carried out to collect information on the market, and its peer markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. A bottom-up approach was employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

The secondary sources referred to for this research study include publications from public sources, such as the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, World Obesity Federation, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, among others. Secondary sources also include business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global GLP-1 Analogue market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand side of the market were interviewed to obtain qualitative and quantitative information.

GLP-1 Analogues Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

A bottom-up approach was used to estimate and validate the total size of the GLP-1 Analogues market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The list of approved GLP-1 analogues was identified through extensive secondary and primary research.  
  • The revenues generated from these GLP-1 Analogues have been determined through annual reports, and secondary sources (including paid database)
  • The products were mapped as per the segments of the market. Percentage shares, splits were determined based on the revenue contributed to each of the segments. This was verified using secondary sources and by industry experts

Global GLP-1 Analogue Market Size: Bottom-up Approach

GLP-1 Analogues Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

GLP-1 Analogues Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Glucagon-like peptide 1 (GLP-1) Analogues, alternatively termed GLP-1 receptor agonists, are drugs designed to mimic the incretin hormone glucagon-like peptide-1 (GLP-1). These drugs are primarily used for the treatment of type 2 diabetes mellitus and, more recently, obesity. They stimulate insulin secretion, inhibit glucagon release, and slow gastric emptying, which aids in lowering blood sugar levels and promotes satiety. This market is for these GLP-1 Analogues administered as a single drug or in combination with other receptor agonists, such as insulin.

Key Stakeholders

  • Pharmaceutical & biotechnology companies
  • Hospitals
  • Specialty clinics
  • Long-term care facilities
  • Academic researchers and government research organizations
  • Private research institutes
  • Contract manufacturing organizations (CMOs)
  • Contract research organizations (CROs)
  • Venture capitalists

Report Objectives

  • To define, describe, and forecast the global GLP-1 Analogues market by product, format, route of administration, indication, end user, and region
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall GLP-1 Analogue market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
  • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To strategically analyze the market structure and profile the key players of the global GLP-1 Analogues market and comprehensively analyze their core competencies2
  • To track and analyze competitive developments such as expansions, acquisitions, partnerships, collaborations, agreements, and product launches in the GLP-1 Analogues market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographical Analysis

  • Further breakdown of the Rest of Europe GLP-1 analogues market, by country
  • Further breakdown of the Rest of Asia Pacific GLP-1 analogues market, by country
  • Further breakdown of the Rest of Latin America GLP-1 analogues market, by country

Segment Analysis

  • Further breakdown of the therapeutic indication segment as per the product portfolio of prominent players operating in the market

Customization

  • The following customization options are available for the report:
  • Analysis on CDMO services for GLP-1 analogues and other preclinical and clinical GLP-1 analogues services

Previous Versions of this Report

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in GLP-1 Analogues Market

DMCA.com Protection Status